These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 38232909)
1. Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project. Ingrasciotta Y; Spini A; L'Abbate L; Fiore ES; Carollo M; Ientile V; Isgrò V; Cavazzana A; Biasi V; Rossi P; Ejlli L; Belleudi V; Poggi F; Sapigni E; Puccini A; Ancona D; Stella P; Pollina Addario S; Allotta A; Leoni O; Zanforlini M; Tuccori M; Gini R; Trifirò G Pharmacol Res; 2024 Feb; 200():107074. PubMed ID: 38232909 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy. Ingrasciotta Y; Fontana A; Mancuso A; Ientile V; Sultana J; Uomo I; Pastorello M; Calabrò P; Andò G; Trifirò G Pharmaceuticals (Basel); 2021 Mar; 14(4):. PubMed ID: 33805899 [TBL] [Abstract][Full Text] [Related]
3. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. Trifirò G; Isgrò V; Ingrasciotta Y; Ientile V; L'Abbate L; Foti SS; Belleudi V; Poggi F; Fontana A; Moretti U; Lora R; Sabaini A; Senesi I; Sorrentino C; Puzo MR; Padula A; Fusco M; Giordana R; Solfrini V; Puccini A; Rossi P; Del Zotto S; Leoni O; Zanforlini M; Ancona D; Bavaro V; Garau D; Ledda S; Scondotto S; Allotta A; Tuccori M; Gini R; Bucaneve G; Franchini D; Cavazzana A; Biasi V; Spila Alegiani S; Massari M; BioDrugs; 2021 Nov; 35(6):749-764. PubMed ID: 34637126 [TBL] [Abstract][Full Text] [Related]
4. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD; Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358 [TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project. Spini A; L'Abbate L; Ingrasciotta Y; Pellegrini G; Carollo M; Ientile V; Leoni O; Zanforlini M; Ancona D; Stella P; Cavazzana A; Scapin A; Lopes S; Belleudi V; Trifirò G Clin Epidemiol; 2024; 16():395-407. PubMed ID: 38854895 [TBL] [Abstract][Full Text] [Related]
6. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Borren NZ; Ananthakrishnan AN Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024 [TBL] [Abstract][Full Text] [Related]
7. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study. Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662 [TBL] [Abstract][Full Text] [Related]
8. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Wu N; Lee YC; Shah N; Harrison DJ Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652 [TBL] [Abstract][Full Text] [Related]
9. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. Wu JJ; Pelletier C; Ung B; Tian M J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520 [TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
11. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296 [TBL] [Abstract][Full Text] [Related]
12. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis. Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624 [TBL] [Abstract][Full Text] [Related]
13. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting. Zagni E; Colombo D; Fiocchi M; Perrone V; Sangiorgi D; Andretta M; De Sarro G; Nava E; Degli Esposti L Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):491-497. PubMed ID: 32701033 [TBL] [Abstract][Full Text] [Related]
14. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM). Sbidian E; Mezzarobba M; Weill A; Coste J; Rudant J Br J Dermatol; 2019 Jan; 180(1):86-93. PubMed ID: 29791721 [TBL] [Abstract][Full Text] [Related]
15. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869 [TBL] [Abstract][Full Text] [Related]
16. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials. Malatestinic W; Nordstrom B; Wu JJ; Goldblum O; Solotkin K; Lin CY; Kistler K; Fraeman K; Johnston J; Hawley LL; Sicignano N; Araujo A J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450 [TBL] [Abstract][Full Text] [Related]
17. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491 [TBL] [Abstract][Full Text] [Related]
18. Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries. Oppelt KA; Kuiper JG; Ingrasciotta Y; Ientile V; Herings RMC; Tari M; Trifirò G; Haug U Front Oncol; 2021; 11():630456. PubMed ID: 33747950 [No Abstract] [Full Text] [Related]
19. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481 [TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]